Adding smartphone-based cognitive-behavior therapy to pharmacotherapy for major depression (FLATT project): Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Watanabe, Norio ^a   Horikoshi, Masaru ^a   Yamada, Mitsuhiko ^a   Shimodera, Shinji ^b   Akechi, Tatsuo ^c   Miki, Kazuhira ^d   Inagaki, Masatoshi ^e   Yonemoto, Naohiro ^a   Imai, Hissei ^f   Tajika, Aran ^f   Ogawa, Yusuke ^f   Takeshima, Nozomi ^f   Hayasaka, Yu ^f   Furukawa, Toshi A ^f  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d Miki Clinic   (Japan)

^e OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Behavior therapy; Cognitive therapy; Computer assisted therapy; Depression; Randomized controlled trials

Indexed keywords

ESCITALOPRAM; SERTRALINE; ANTIDEPRESSANT AGENT;

ADULT; ANAPHYLAXIS; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; COMA; CONTROLLED STUDY; CONVULSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FATIGUE; FEMALE; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER FAILURE; MAJOR DEPRESSION; MALE; MOBILE APPLICATION; MOBILE PHONE; MULTICENTER STUDY; NAUSEA; PATIENT HEALTH QUESTIONNAIRE 9; PATIENT SATISFACTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEROTONIN SYNDROME; SOMNOLENCE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; XEROSTOMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DEVICES; JAPAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUESTIONNAIRE; REMISSION; SMARTPHONE; TIME FACTOR;

ANTIDEPRESSIVE AGENTS; CLINICAL PROTOCOLS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG SUBSTITUTION; HUMANS; JAPAN; PATIENT SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; RESEARCH DESIGN; SMARTPHONE; SURVEYS AND QUESTIONNAIRES; THERAPY, COMPUTER-ASSISTED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84937036323     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0805-z     Document Type: Article

References (35)

1. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
2. Sado M, Yamauchi K, Kawakami N, Ono Y, Furukawa TA, Tsuchiya M, et al. Cost of depression among adults in Japan in 2005. Psychiatry Clin Neurosci. 2011;65(5):442-50.
3. Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry. 2004;4:37.
4. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR * D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
5. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry. 2008;69(11):1675-85. quiz 1839-1641.
6. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70(9):1219-29.
7. Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS One. 2010;5(10):e13196.
8. So M, Yamaguchi S, Hashimoto S, Sado M, Furukawa TA, McCrone P. Is computerised CBT really helpful for adult depression? A meta-analytic re-evaluation of CCBT for adult depression in terms of clinical implementation and methodological validity. BMC Psychiatry. 2013;13(1):113.
9. Watts S, Mackenzie A, Thomas C, Griskaitis A, Mewton L, Williams A, et al. CBT for depression: a pilot RCT comparing mobile phone vs. computer. BMC Psychiatry. 2013;13:49.
10. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-58.
11. Furukawa TA, Horikoshi M, Kawakami N, Kadota M, Sasaki M, Sekiya Y, et al. Telephone cognitive-behavioral therapy for subthreshold depression and presenteeism in workplace: a randomized controlled trial. PLoS One. 2012;7(4):e35330.
12. Ludman EJ, Simon GE, Tutty S, Von Korff M. A randomized trial of telephone psychotherapy and pharmacotherapy for depression: continuation and durability of effects. J Consult Clin Psychol. 2007;75(2):257-66.
13. Simon GE, Ludman EJ, Rutter CM. Incremental benefit and cost of telephone care management and telephone psychotherapy for depression in primary care. Arch Gen Psychiatry. 2009;66(10):1081-9.
14. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
15. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282(18):1737-44.
16. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;13:23-9.
17. Vetter VL. Clues or miscues? How to make the right interpretation and correctly diagnose long-QT syndrome. Circulation. 2007;115(20):2595-8.
18. Spitzer RL, Williams JW, Kroenke K, Linzer M, deGruy 3rd FV, Hahn SR, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the prime-md 1000 study. JAMA. 1994;272(22):1749-56.
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-71.
20. Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory, Second Edition, Manual. San Antonio: The Psychological Corporation; 1996.
21. Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, et al. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res. 2005;135(3):229-35.
22. Pinto-Meza A, Serrano-Blanco A, Penarrubia MT, Blanco E, Haro JM. Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? J Gen Intern Med. 2005;20(8):738-42.
23. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.
24. Lowe B, Unutzer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004;42(12):1194-201.
25. Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12(2):71-9.
26. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32(6):959-76.
27. Cornelius B, Groothoff J, van der Klink J, Brouwer S. The performance of the K10, K6 and GHQ-12 to screen for present state DSM-IV disorders among disability claimants. BMC Public Health. 2013;13(1):128.
28. Furukawa TA, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y, et al. The performance of the Japanese version of the K6 and K10 in the World Mental Health Survey Japan. Int J Methods Psychiatr Res. 2008;17(3):152-8.
29. Hirayasu Y. A dose-response and non-inferiority study evaluating the efficacy and safety of escitalopram in patients with major depressive disorder: a placebo- and paroxetine-controlled, double-blind, comparative study. Japanese J Clin Psychopharmacol. 2011;14(5):883-99.
30. Hirayasu Y. A dose-response study of escitalopram in patients with major depressive disorder: a placebo-controlled, double-blind study. Japanese J Clin Psychopharmacol. 2011;14(5):871-82.
31. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;2:CD006532.
32. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.
33. Cohen J. Statistical power analysis in the behavioral sciences. Hillsdale: Erlbaum; 1988.
34. Diggle PJ, Heagerty PJ, Liang K, Zeger SL. Analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.
35. Furukawa TA, Noma H, Caldwell DM, Honyashiki M, Shinohara K, Imai H, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand. 2014;130(3):181-92.